Clinical characteristics of study subjects
| Characteristic . | Data . |
|---|---|
| Age, y* | 33.5 (7-57) |
| Follow-up, d* | 221 (31-905) |
| Survival, d* | 224 (31-1309) |
| Sex, n (%) | |
| Female | 9 (28.1) |
| Male | 23 (71.9) |
| Diagnosis, n (%) | |
| ALL | 10 (31.2) |
| AML/MDS | 6 (18.8) |
| CLL | 2 (6.2) |
| CML/MPD | 2 (6.2) |
| Hodgkin's Disease | 8 (25) |
| NHL | 4 (12.5) |
| Prior treatment characteristics, n | |
| No. of prior regimens for AML subjects, n* | 3 (1-8) |
| Hodgkin Disease/NHL patients with prior autologous SC transplantation, n (%) | 12 (100) |
| Preparative regimen, n (%) | |
| Cyclophosphamide/fludarabine/TBI (200 Gy)/ thymoglobulin/rituximab | 1 (3.1) |
| Fludarabine/IV busulfan/thymoglobulin | 7 (21.9) |
| Fludarabine/melphalan/thymoglobulin | 1 (3.1) |
| Fludarabine/melphalan/thymoglobulin/rituximab | 2 (6.2) |
| Fludarabine/melphalan/thiotepa/thymoglobulin/rituximab | 3 (9.4) |
| Fludarabine/melphalan/thiotepa/thymoglobulin | 18 (56.2) |
| Pretransplant CMV seropositivity, n (%) | |
| Positive | 22 (69) |
| Negative | 10 (31) |
| Degree of HLA match, n (%) | |
| 3/6 | 1 (3.1) |
| 4/6 | 18 (56.3) |
| 5/6 | 13 (40.6) |
| Total nucleated cells per kg infused (×106)* | 33.5 (11.1-60.7) |
| CD34 infused/kg (×105)* | 1.23 (0.15-49.9) |
| Complete blood count subsets at day 30, ×109/L* | |
| White blood count | 2.25 (0.4-17.8) |
| Absolute neutrophil count | 1.48 (0.19-16.2) |
| Absolute monocyte count | 0.36 (0.13-1.2) |
| Absolute lymphocyte count | 0.21 (0.1-1.15) |
| Complete blood count subsets at day 60, ×109/L* | |
| White blood count | 4.40 (1.3-21.0) |
| Absolute neutrophil count | 4.44 (0.08-14.91) |
| Absolute monocyte count | 0.44 (0.01-2.45) |
| Absolute lymphocyte count | 0.58 (0.1-2.35) |
| Characteristic . | Data . |
|---|---|
| Age, y* | 33.5 (7-57) |
| Follow-up, d* | 221 (31-905) |
| Survival, d* | 224 (31-1309) |
| Sex, n (%) | |
| Female | 9 (28.1) |
| Male | 23 (71.9) |
| Diagnosis, n (%) | |
| ALL | 10 (31.2) |
| AML/MDS | 6 (18.8) |
| CLL | 2 (6.2) |
| CML/MPD | 2 (6.2) |
| Hodgkin's Disease | 8 (25) |
| NHL | 4 (12.5) |
| Prior treatment characteristics, n | |
| No. of prior regimens for AML subjects, n* | 3 (1-8) |
| Hodgkin Disease/NHL patients with prior autologous SC transplantation, n (%) | 12 (100) |
| Preparative regimen, n (%) | |
| Cyclophosphamide/fludarabine/TBI (200 Gy)/ thymoglobulin/rituximab | 1 (3.1) |
| Fludarabine/IV busulfan/thymoglobulin | 7 (21.9) |
| Fludarabine/melphalan/thymoglobulin | 1 (3.1) |
| Fludarabine/melphalan/thymoglobulin/rituximab | 2 (6.2) |
| Fludarabine/melphalan/thiotepa/thymoglobulin/rituximab | 3 (9.4) |
| Fludarabine/melphalan/thiotepa/thymoglobulin | 18 (56.2) |
| Pretransplant CMV seropositivity, n (%) | |
| Positive | 22 (69) |
| Negative | 10 (31) |
| Degree of HLA match, n (%) | |
| 3/6 | 1 (3.1) |
| 4/6 | 18 (56.3) |
| 5/6 | 13 (40.6) |
| Total nucleated cells per kg infused (×106)* | 33.5 (11.1-60.7) |
| CD34 infused/kg (×105)* | 1.23 (0.15-49.9) |
| Complete blood count subsets at day 30, ×109/L* | |
| White blood count | 2.25 (0.4-17.8) |
| Absolute neutrophil count | 1.48 (0.19-16.2) |
| Absolute monocyte count | 0.36 (0.13-1.2) |
| Absolute lymphocyte count | 0.21 (0.1-1.15) |
| Complete blood count subsets at day 60, ×109/L* | |
| White blood count | 4.40 (1.3-21.0) |
| Absolute neutrophil count | 4.44 (0.08-14.91) |
| Absolute monocyte count | 0.44 (0.01-2.45) |
| Absolute lymphocyte count | 0.58 (0.1-2.35) |
ALL represents acute lymphocytic leukemia; AML/MDS, acute myeloid leukemia/myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; CML/MPD, chronic myelogenous leukemia/myeloproliferative disease; NHL, non-Hodgkin lymphoma; and TBI, total body irradiation.
Expressed as median (range).